276 related articles for article (PubMed ID: 18350378)
1. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
2. Copaxone interferes with the PrP Sc-GAG interaction.
Engelstein R; Ovadia H; Gabizon R
Eur J Neurol; 2007 Aug; 14(8):877-84. PubMed ID: 17662008
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.
Wolf H; Graßmann A; Bester R; Hossinger A; Möhl C; Paulsen L; Groschup MH; Schätzl H; Vorberg I
J Virol; 2015 Oct; 89(19):9853-64. PubMed ID: 26202247
[TBL] [Abstract][Full Text] [Related]
4. The metabolism of glycosaminoglycans is impaired in prion diseases.
Mayer-Sonnenfeld T; Zeigler M; Halimi M; Dayan Y; Herzog C; Lasmezas CI; Gabizon R
Neurobiol Dis; 2005 Dec; 20(3):738-43. PubMed ID: 15951190
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl sulfoxide delays PrP sc accumulation and disease symptoms in prion-infected hamsters.
Shaked GM; Engelstein R; Avraham I; Kahana E; Gabizon R
Brain Res; 2003 Sep; 983(1-2):137-43. PubMed ID: 12914974
[TBL] [Abstract][Full Text] [Related]
6. PrPSc incorporation to cells requires endogenous glycosaminoglycan expression.
Hijazi N; Kariv-Inbal Z; Gasset M; Gabizon R
J Biol Chem; 2005 Apr; 280(17):17057-61. PubMed ID: 15668233
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
[TBL] [Abstract][Full Text] [Related]
8. Virus-induced alterations of membrane lipids affect the incorporation of PrP Sc into cells.
Avrahami D; Dayan-Amouyal Y; Tal S; Mincberg M; Davis C; Abramsky O; Gabizon R
J Neurosci Res; 2008 Sep; 86(12):2753-62. PubMed ID: 18478553
[TBL] [Abstract][Full Text] [Related]
9. A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.
Bajsarowicz K; Ahn M; Ackerman L; Dearmond BN; Carlson G; DeArmond SJ
J Neuropathol Exp Neurol; 2012 May; 71(5):449-66. PubMed ID: 22507918
[TBL] [Abstract][Full Text] [Related]
10. Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrP
Pankiewicz JE; Sanchez S; Kirshenbaum K; Kascsak RB; Kascsak RJ; Sadowski MJ
Mol Neurobiol; 2019 Mar; 56(3):2073-2091. PubMed ID: 29987703
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.
Ertmer A; Gilch S; Yun SW; Flechsig E; Klebl B; Stein-Gerlach M; Klein MA; Schätzl HM
J Biol Chem; 2004 Oct; 279(40):41918-27. PubMed ID: 15247213
[TBL] [Abstract][Full Text] [Related]
12. Characterization of intracellular dynamics of inoculated PrP-res and newly generated PrP(Sc) during early stage prion infection in Neuro2a cells.
Yamasaki T; Baron GS; Suzuki A; Hasebe R; Horiuchi M
Virology; 2014 Feb; 450-451():324-35. PubMed ID: 24503096
[TBL] [Abstract][Full Text] [Related]
13. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy.
Heiseke A; Aguib Y; Riemer C; Baier M; Schätzl HM
J Neurochem; 2009 Apr; 109(1):25-34. PubMed ID: 19183256
[TBL] [Abstract][Full Text] [Related]
14. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
Korth C; May BC; Cohen FE; Prusiner SB
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9836-41. PubMed ID: 11504948
[TBL] [Abstract][Full Text] [Related]
15. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
[TBL] [Abstract][Full Text] [Related]
17. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
18. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice.
Hara H; Miyata H; Das NR; Chida J; Yoshimochi T; Uchiyama K; Watanabe H; Kondoh G; Yokoyama T; Sakaguchi S
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046443
[TBL] [Abstract][Full Text] [Related]
19. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions.
Bian J; Kang HE; Telling GC
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):6028-33. PubMed ID: 24711410
[TBL] [Abstract][Full Text] [Related]
20. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions.
Petsch B; Müller-Schiffmann A; Lehle A; Zirdum E; Prikulis I; Kuhn F; Raeber AJ; Ironside JW; Korth C; Stitz L
J Virol; 2011 May; 85(9):4538-46. PubMed ID: 21345946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
